EA201301277A1 - Композиции и способы лечения заболеваний сетчатки - Google Patents

Композиции и способы лечения заболеваний сетчатки

Info

Publication number
EA201301277A1
EA201301277A1 EA201301277A EA201301277A EA201301277A1 EA 201301277 A1 EA201301277 A1 EA 201301277A1 EA 201301277 A EA201301277 A EA 201301277A EA 201301277 A EA201301277 A EA 201301277A EA 201301277 A1 EA201301277 A1 EA 201301277A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
improving
compositions
diseases
mesh
Prior art date
Application number
EA201301277A
Other languages
English (en)
Other versions
EA026193B1 (ru
Inventor
Генри Классен
Цзин Ян
Original Assignee
Те Риджентс Оф Те Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47177629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201301277(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Те Риджентс Оф Те Юниверсити Оф Калифорния filed Critical Те Риджентс Оф Те Юниверсити Оф Калифорния
Publication of EA201301277A1 publication Critical patent/EA201301277A1/ru
Publication of EA026193B1 publication Critical patent/EA026193B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)

Abstract

В документе описываются композиции и способы лечения, ослабления или предотвращения заболеваний или состояний сетчатки; улучшения фотопического (дневного) зрения; коррекции остроты зрения, улучшения функции макулы, улучшения показателей поля зрения, улучшения скотопического (ночного) зрения путем введения клеток-предшественников сетчатки. Описанный здесь объект изобретения также предоставляет клеточные популяции, содержащие клетки-предшественники сетчатки, и способы их выделения.
EA201301277A 2011-05-18 2012-05-17 Композиции и способы лечения заболеваний сетчатки EA026193B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487419P 2011-05-18 2011-05-18
PCT/US2012/038342 WO2012158910A2 (en) 2011-05-18 2012-05-17 Compositions and methods for treating retinal diseases

Publications (2)

Publication Number Publication Date
EA201301277A1 true EA201301277A1 (ru) 2014-04-30
EA026193B1 EA026193B1 (ru) 2017-03-31

Family

ID=47177629

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201301277A EA026193B1 (ru) 2011-05-18 2012-05-17 Композиции и способы лечения заболеваний сетчатки

Country Status (14)

Country Link
US (8) US9107897B2 (ru)
EP (3) EP3824910A1 (ru)
JP (8) JP6223963B2 (ru)
KR (1) KR101972610B1 (ru)
CN (3) CN103687626B (ru)
AU (1) AU2012255735B2 (ru)
BR (1) BR112013029663A2 (ru)
CA (1) CA2835215C (ru)
EA (1) EA026193B1 (ru)
HK (1) HK1221739A1 (ru)
IL (2) IL229257B (ru)
MX (1) MX350951B (ru)
SG (2) SG10201912961QA (ru)
WO (1) WO2012158910A2 (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026193B1 (ru) 2011-05-18 2017-03-31 Те Риджентс Оф Те Юниверсити Оф Калифорния Композиции и способы лечения заболеваний сетчатки
US8563304B2 (en) * 2011-06-14 2013-10-22 The Schepens Eye Research Institute Low oxygen culture conditions for maintaining retinal progenitor cell multipotency
BR112014019328A8 (pt) 2012-02-17 2017-07-11 The Schepens Eye Res Institute Perfil de fenótipo de células progenitoras retinais humanas
US10980865B2 (en) * 2012-08-10 2021-04-20 Aquavit Pharmaceuticals, Inc. Direct application system and method for the delivery of bioactive compositions and formulations
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US10307444B2 (en) 2013-03-15 2019-06-04 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
JP6651440B2 (ja) 2013-10-09 2020-02-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 哺乳動物の網膜幹細胞の生産方法及び適用
US10930373B2 (en) * 2014-03-24 2021-02-23 Life Technologies Corporation Methods and systems for knowledge discovery using biological data
WO2016021894A1 (ko) * 2014-08-04 2016-02-11 영남대학교 산학협력단 Ｃｄ９ 항체를 유효성분으로 함유하는 세포노화 또는 노화 관련 질환 예방 또는 치료용 약학조성물
IL273405B2 (en) * 2014-12-30 2024-01-01 Cell Cure Neurosciences Ltd RPE cell populations and methods for their production
CN106318909B (zh) * 2015-06-23 2019-04-05 何伟 一种具有治疗视网膜退行性病变功能的视网膜祖细胞及其制剂
WO2017026694A1 (ko) * 2015-08-11 2017-02-16 영남대학교 산학협력단 Cd9 항체를 유효성분으로 함유하는 안질환 예방 또는 치료용 약학 조성물
AU2016320991C1 (en) * 2015-09-08 2023-04-06 Healios K.K. Method for producing retinal pigment epithelial cells
US10891729B2 (en) * 2015-11-18 2021-01-12 University Of Louisville Research Foundation, Inc. Automated methods for the objective quantification of retinal characteristics by retinal region and diagnosis of retinal pathology
WO2018106414A1 (en) * 2016-12-07 2018-06-14 Mayo Foundation For Medical Education And Research Methods and materials for using fibrin supports for retinal pigment epithelium transplantation
EP3332695B1 (en) * 2016-12-09 2021-05-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Measurement device
CN106822182A (zh) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 一种细胞提取物及其用途
EP3570851A4 (en) * 2017-01-17 2021-03-03 Tufts Medical Center, Inc. ADOPTIVE TRANSFER OF PLASMACYTOID DENDRITIC CELLS TO PREVENT OR TREAT EYE DISEASES AND CONDITIONS
EP3634438A4 (en) * 2017-06-05 2021-03-03 The Regents of The University of California COMPOSITIONS FOR THE TREATMENT OF RETINAL DISEASES AND THEIR PRODUCTION AND USE METHODS
CN117379543A (zh) * 2017-08-20 2024-01-12 加州大学董事会 治疗青光眼的Wnt5a的调节
US20220175844A1 (en) * 2018-02-02 2022-06-09 University Of Maryland, Baltimore Methods of treating optic nerve diseases using neural progenitor cell growth factors
EP3758657A4 (en) * 2018-03-02 2022-01-19 The Schepens Eye Research Institute, Inc. SYSTEM AND METHOD OF TREATMENT OF MEIBOMAN GLAND DYSFUNCTION
CN108507989B (zh) * 2018-03-28 2021-10-26 韶关学院 双抗体夹心免疫竞争法检测奥沙普嗪的量子点免疫层析检测卡及检测方法
FI3810758T3 (sv) * 2018-06-20 2023-10-11 Biolamina Ab Förfaranden och sammansättningar för framställning av retinala pigmentepitelceller
CN110755427A (zh) * 2018-07-28 2020-02-07 华中科技大学 一种治疗视网膜退行性疾病的药物
RU2707264C1 (ru) * 2018-09-26 2019-11-25 ФГБНУ "НИИ глазных болезней" Способ трансплантации стволовых клеток при повреждении пигментного эпителия сетчатки в эксперименте
BR112021006065A2 (pt) 2018-09-27 2021-07-20 The Regents Of The University Of California ensaios para terapias e tratamentos à base de célula
AU2019351134A1 (en) * 2018-09-27 2021-04-15 The Regents Of The University Of California Methods of human retinal progenitor cell isolation and culture
CN109136187A (zh) * 2018-09-29 2019-01-04 浙江省人民医院 一种人颅骨间充质干细胞诱导分化神经细胞的方法
US20220105157A1 (en) * 2019-01-04 2022-04-07 The Regents Of The University Of California Compositions and Methods for Promoting Angiogenesis in the Eye
US20220354896A1 (en) * 2019-04-28 2022-11-10 Lineage Cell Therapeutics, Inc. Compositions and methods for the treatment of retinal degeneration
CN110527698B (zh) * 2019-08-23 2021-10-01 温氏食品集团股份有限公司 一种利用小分子化合物提高基因组定点插入效率的方法
CN110548143A (zh) * 2019-09-17 2019-12-10 武汉大学 大麻素受体cb1在视网膜感光细胞退行性疾病中的应用
CN112807275B (zh) * 2019-11-15 2022-05-20 湖北远大天天明制药有限公司 一种眼用组合物及其制备方法与应用
EP4058036A1 (en) * 2019-11-15 2022-09-21 Neoprogen, Inc. Immortalized cardiac stem cells for cardiac repair
CN111793683B (zh) * 2020-08-06 2021-04-27 复旦大学附属眼耳鼻喉科医院 一种糖尿病视网膜病变检测生物标记物、检测试剂盒及应用
CN111926074B (zh) * 2020-09-03 2021-04-23 南京医科大学眼科医院 一种缺血性视网膜病变检测生物标记物、检测试剂盒及应用
CN114917367A (zh) * 2021-06-02 2022-08-19 中国科学院动物研究所 Lhx2在促进中枢系统神经元的损伤修复再生中的应用
WO2023278382A1 (en) 2021-06-29 2023-01-05 Staffan Holmin Endoluminal delivery cannula
CN113444789A (zh) * 2021-08-27 2021-09-28 中国医学科学院北京协和医院 青光眼相关生物标志物及其应用
WO2023211857A1 (en) 2022-04-25 2023-11-02 Lineage Cell Therapeutics, Inc. Methods and compositions for treating vision loss
WO2023215602A1 (en) * 2022-05-06 2023-11-09 The Schepens Eye Research Institute, Inc. Isolation, enrichment, and expansion of human rod progenitor cells and extracellular vesicles derived therefrom
CN115216445B (zh) * 2022-08-04 2023-11-14 辽宁何氏医学院 培养基及其在培养视网膜祖细胞中的应用
WO2024044134A1 (en) * 2022-08-23 2024-02-29 Astellas Institute For Regenerative Medicine Photoreceptor rescue cell (prc) compositions and methods for treatment of ocular disorders

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868121A (en) 1985-02-07 1989-09-19 Mcdonnell Douglas Corporation Islet isolation process
US5079160A (en) 1987-06-08 1992-01-07 Lacy Paul E Method to isolate clusters of cell subtypes from organs
US5270192A (en) 1991-02-07 1993-12-14 Monsanto Company Biological artificial liver
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6045791A (en) 1992-03-06 2000-04-04 Photogenesis, Inc. Retinal pigment epithelium transplantation
US5422261A (en) 1993-04-16 1995-06-06 Baxter International Inc. Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US6933331B2 (en) 1998-05-22 2005-08-23 Nanoproducts Corporation Nanotechnology for drug delivery, contrast agents and biomedical implants
CA2216439A1 (en) 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
BR9809284A (pt) * 1997-04-21 2004-08-03 Univ Florida Construto e processo para expressão de polinucleotìdeo em altos nìveis
US6289377B1 (en) 1997-11-10 2001-09-11 General Instrument Corporation Dynamic network configuration of a one-way adapter using a proxy agent that communicates with a resource server through a configured return path adapter
US6886568B2 (en) 1998-04-08 2005-05-03 The Johns Hopkins University Method for fabricating cell-containing implants
US6184035B1 (en) 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
NZ513303A (en) * 1999-02-04 2003-03-28 Technion Res & Dev Foundation Three dimensional plug flow bioreactor, and its use for the maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US7105150B2 (en) 1999-02-12 2006-09-12 Stemcells California, Inc. In vivo screening methods using enriched neural stem cells
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
EP1226239A4 (en) * 1999-10-15 2003-02-12 Advanced Cell Tech Inc Process for the preparation of differentiated progenitor cells and embryonic stem cells with line defects
JP2003521910A (ja) * 2000-02-11 2003-07-22 ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド 網膜幹細胞の分離及び移植
WO2002076386A2 (en) 2001-03-26 2002-10-03 Zymogenetics, Inc. Method of inducing proliferation of retinal stem cells
DE60230774D1 (de) 2001-04-20 2009-02-26 Children S Hospital Of Orange Isolierung von nervenstammzellen unter verwendung von gangliosiden und anderen oberflächenmarkern
WO2002088332A1 (fr) 2001-04-24 2002-11-07 Hokkaido Technology Licensing Office Co.,Ltd. Colonie riche en petites cellules hepatiques, procede d'obtention de cette colonie, procede d'induction de la maturation de cette colonie dans un tissu hepatique et procede d'estimation de l'effet d'un medicament faisant appel a cette colonie riche en petites cellules hepatiques mature
JP4677538B2 (ja) 2001-06-12 2011-04-27 ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 眼内薬物送達のためのリザーバデバイス
US7166133B2 (en) 2002-06-13 2007-01-23 Kensey Nash Corporation Devices and methods for treating defects in the tissue of a living being
CN1219053C (zh) 2002-08-19 2005-09-14 上海第二医科大学附属第九人民医院 同种异体组织工程化软骨及应用
CA2494450A1 (en) 2002-08-27 2004-03-11 Stemcells, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
CN1506042A (zh) 2002-12-11 2004-06-23 苏加璐 使用来自胎儿细胞和组织的化合物改善皮肤状况的方法和组合物
CN100349621C (zh) 2002-12-18 2007-11-21 上海第二医科大学附属第九人民医院 骨髓基质干细胞诱导成软骨的方法
US7241455B2 (en) 2003-04-08 2007-07-10 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing radiation-crosslinked polymer for controlled delivery of a therapeutic agent
JP4708342B2 (ja) 2003-07-25 2011-06-22 デックスコム・インコーポレーテッド 埋設可能な装置に用いる酸素増大膜システム
US20050048021A1 (en) 2003-08-27 2005-03-03 Robert Salem Proportional method for diagnosing and appropriately cleansing and conditioning hair and a kit of proportional shampoos and conditioners for practicing the method
KR20060085246A (ko) 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
US7794706B2 (en) 2003-10-14 2010-09-14 Medivas, Llc Bioactive wound dressings and implantable devices and methods of use
SG10201606441SA (en) * 2004-01-23 2016-09-29 Astellas Inst For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP1796693A2 (en) 2004-08-26 2007-06-20 Chandrashekhar P. Pathak Implantable tissue compositions and method
US7351423B2 (en) 2004-09-01 2008-04-01 Depuy Spine, Inc. Musculo-skeletal implant having a bioactive gradient
MX2007006245A (es) * 2004-12-08 2007-07-25 Sirion Therapeutics Inc Metodos, analisis y composiciones para tratar enfermedades relacionadas con retinol.
US7759120B2 (en) 2005-03-02 2010-07-20 Kps Bay Medical, Inc. Seeding implantable medical devices with cells
US7541186B2 (en) 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
WO2007130060A2 (en) * 2006-05-03 2007-11-15 Schepens Eye Research Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues
US9061017B2 (en) * 2006-05-03 2015-06-23 The Schepens Eye Research Institute, Inc. Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues
AU2007200990B8 (en) 2006-11-21 2011-05-12 Living Cell Technologies Limited Cell Implantation To Prevent and/or Treat Hearing Loss
KR101849336B1 (ko) 2007-10-12 2018-04-16 아스텔라스 인스티튜트 포 리제너러티브 메디슨 Ｒｐｅ 세포의 개선된 생산 방법 및 ｒｐｅ 세포의 조성물
CA2721952C (en) 2008-04-22 2019-11-12 Regenerative Research Foundation Retinal pigment epithelial stem cells
US8425473B2 (en) 2009-01-23 2013-04-23 Iscience Interventional Corporation Subretinal access device
AU2010213612B2 (en) 2009-02-12 2015-04-30 Incept, Llc Drug delivery through hydrogel plugs
KR101268741B1 (ko) * 2009-10-06 2013-06-04 김지연 줄기세포를 망막세포로 분화시키는 방법
DE202009018859U1 (de) 2009-11-10 2014-04-01 Fluoron Gmbh Spritze zur Injektion eines chirurgischen Gases
EA026193B1 (ru) 2011-05-18 2017-03-31 Те Риджентс Оф Те Юниверсити Оф Калифорния Композиции и способы лечения заболеваний сетчатки
US8563304B2 (en) 2011-06-14 2013-10-22 The Schepens Eye Research Institute Low oxygen culture conditions for maintaining retinal progenitor cell multipotency

Also Published As

Publication number Publication date
US10822585B2 (en) 2020-11-03
JP2023030176A (ja) 2023-03-07
IL260585B (en) 2019-08-29
EP2709672A2 (en) 2014-03-26
JP2020054363A (ja) 2020-04-09
US9963675B2 (en) 2018-05-08
CN105349492A (zh) 2016-02-24
JP6223963B2 (ja) 2017-11-01
CN105349492B (zh) 2019-04-16
BR112013029663A2 (pt) 2020-07-21
KR101972610B1 (ko) 2019-04-25
JP2017035108A (ja) 2017-02-16
US20200157498A1 (en) 2020-05-21
HK1221739A1 (zh) 2017-06-09
US10781422B1 (en) 2020-09-22
US20240026290A1 (en) 2024-01-25
EP2709672B1 (en) 2019-12-18
CN103687626B (zh) 2020-06-30
MX2013013434A (es) 2014-09-04
US20140186309A1 (en) 2014-07-03
US20150328262A1 (en) 2015-11-19
MX350951B (es) 2017-09-26
US20200325444A1 (en) 2020-10-15
CN103687626A (zh) 2014-03-26
JP2021164464A (ja) 2021-10-14
US20210189333A1 (en) 2021-06-24
CA2835215C (en) 2023-10-10
JP6571252B2 (ja) 2019-09-04
JP2023030175A (ja) 2023-03-07
AU2012255735A1 (en) 2013-11-28
EA026193B1 (ru) 2017-03-31
IL229257A0 (en) 2014-01-30
SG194843A1 (en) 2013-12-30
US9107897B2 (en) 2015-08-18
SG10201912961QA (en) 2020-03-30
JP6931340B2 (ja) 2021-09-01
US20190085287A1 (en) 2019-03-21
WO2012158910A2 (en) 2012-11-22
CA2835215A1 (en) 2012-11-22
EP3636286A1 (en) 2020-04-15
EP2709672A4 (en) 2014-12-31
IL229257B (en) 2018-08-30
JP2018186832A (ja) 2018-11-29
AU2012255735B2 (en) 2017-05-25
US11739294B2 (en) 2023-08-29
EP3824910A1 (en) 2021-05-26
US10752882B2 (en) 2020-08-25
CN111265551A (zh) 2020-06-12
JP2014515261A (ja) 2014-06-30
JP7232524B2 (ja) 2023-03-03
JP2018188469A (ja) 2018-11-29
WO2012158910A3 (en) 2013-02-28
KR20140033431A (ko) 2014-03-18
US20160319243A1 (en) 2016-11-03
US10041041B2 (en) 2018-08-07

Similar Documents

Publication Publication Date Title
EA201301277A1 (ru) Композиции и способы лечения заболеваний сетчатки
PH12018500401B1 (en) Antibodies specific for tgf-beta
BR112014008759A2 (pt) tratamento de doença ocular
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015501558A1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
MY171920A (en) Prevention and treatment of ocular conditions
EP4233545A3 (en) Synergistic bacterial compositions and methods of production and use thereof
PH12014502449A1 (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
EA201201030A1 (ru) 5-алкинилпиримидины
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
NZ704247A (en) Compositions and treatment for eye diseases and disorders
MX2013003890A (es) Composiciones y metodos para tratar edema ocular, neovascularizacion y enfermedades relacionadas.
MX344046B (es) Composicion de androgeno para tratar una afeccion oftalmica.
MX362271B (es) Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso.
MX2014002107A (es) Sensibilizantes de (bacterio) clorofila para el tratamiento de enfermedades y transtornos oculares campo tecnico.
MX2021008663A (es) Anticuerpos mejorados contra il-6.
WO2012119070A3 (en) Silicone-based ophthalmic formulations
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
WO2013181339A3 (en) Cyclosporin a analogs
WO2014152754A3 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
WO2014028668A3 (en) Stem cell enhancing therapeutics
MY178169A (en) Topical ophthalmic peptide formulation
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
IN2014CN04809A (ru)